These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Successful management of the Sézary syndrome. Mobilization and removal of extravascular neoplastic T cells by leukapheresis. Edelson R, Facktor M, Andrews A, Lutzner M, Schein P. N Engl J Med; 1974 Aug 08; 291(6):293-4. PubMed ID: 4276213 [No Abstract] [Full Text] [Related]
12. Production of Sézary-like cells from normal human lymphocytes. Yeckley JA, Weston WL, Thorne EG, Krueger GG. Arch Dermatol; 1975 Jan 02; 111(1):29-32. PubMed ID: 123432 [Abstract] [Full Text] [Related]
13. Antilymphocyte globulin in the treatment of advanced Sézary syndrome. Barett AJ, Staughton RC, Brigden D, Byrom N, Roberts JT, Hobbs JR. Lancet; 1976 May 01; 1(7966):940-1. PubMed ID: 57341 [Abstract] [Full Text] [Related]
14. [Cutaneous malignant lymphoproliferative disorders: mycosis fungoide and the Sézary syndrome (author's transl)]. Sánchez-Yus E, González de Canales F. Sangre (Barc); 1978 May 01; 23(2):181-9. PubMed ID: 148742 [No Abstract] [Full Text] [Related]
15. The immunological identification of the Sézary cell. Claudy AL. Br J Dermatol; 1974 Nov 01; 91(5):597-600. PubMed ID: 4279691 [No Abstract] [Full Text] [Related]
16. Morphologic and functional properties of the atypical T lymphocytes of the Sezary syndrome. Edelson RL, Lutzner MA, Kirkpatrick CH, Shevach EM, Green I. Mayo Clin Proc; 1974 Aug 01; 49(8):558-66. PubMed ID: 4277580 [No Abstract] [Full Text] [Related]